<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>a2101140zex-10.htm
<DESCRIPTION>EXHIBIT 10
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03SAN1016_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="ki1016_exhibit_10"> </A>
<A NAME="toc_ki1016_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;10    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>STOCKHOLDERS AGREEMENT  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> dated as of January&nbsp;17, 2003  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> by and among  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> ARENA PHARMACEUTICALS,&nbsp;INC.,  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> BIOTECHNOLOGY VALUE FUND,&nbsp;L.P.,  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> BIOTECHNOLOGY VALUE FUND&nbsp;II,&nbsp;L.P.,  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> BVF INVESTMENTS,&nbsp;L.L.C.,  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> BVF PARTNERS&nbsp;L.P.,  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> BVF&nbsp;INC. and  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> INVESTMENT&nbsp;10,&nbsp;L.L.C.  </B></FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=380177,FOLIO='blank',FILE='DISK022:[03SAN6.03SAN1016]KI1016A.;5',USER='KLECK',CD='18-JAN-2003;06:24' -->
<A NAME="page_ki1016_1_1"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ki1016_table_of_contents"> </A>
<A NAME="toc_ki1016_2"> </A>
<BR></FONT><FONT SIZE=2><B>TABLE OF CONTENTS    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Table of Contents is not part of the Stockholders Agreement to which it is attached but is inserted for convenience only. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="82%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="CENTER"><FONT SIZE=1><B>Page<BR>
No.</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2>ARTICLE&nbsp;I&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>1.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Definitions.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>1</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
ARTICLE&nbsp;II&nbsp;&nbsp;&nbsp;&nbsp;BOARD OF DIRECTORS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
4</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>2.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Composition of Board of Directors.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>4</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>2.02</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Board Committees.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>5</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>2.03</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>BVF Observer.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>6</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>2.04</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Information About BVF Designee and BVF Observer.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>6</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>2.05</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Document Retention Policy.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>6</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
ARTICLE&nbsp;III&nbsp;&nbsp;&nbsp;&nbsp;TRANSFER AND VOTING OF SHARES</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
6</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>3.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Restriction on Certain Transfers.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>6</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>3.02</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Voting of Shares by the Restricted Group.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>6</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
ARTICLE&nbsp;IV&nbsp;&nbsp;&nbsp;&nbsp;STANDSTILL</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
7</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>4.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Limitation on Acquisition of Equity Securities.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>7</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>4.02</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Standstill.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>7</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
ARTICLE&nbsp;V&nbsp;&nbsp;&nbsp;&nbsp;OTHER AGREEMENTS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
8</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>5.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Confidentiality Agreement.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>8</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>5.02</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>No Solicitation.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>8</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>5.03</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Right to Call a Meeting of Company Stockholders.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>8</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>5.04</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Access to Information.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>5.05</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>10b5-1 Program.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
ARTICLE&nbsp;VI&nbsp;&nbsp;&nbsp;&nbsp;OFFER RIGHTS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
9</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>6.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Offer Right.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
ARTICLE&nbsp;VII&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
10</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>7.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Authority.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>10</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>7.02</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>No Conflicts.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>10</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>7.03</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Governmental Approvals and Filings.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>11</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>7.04</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>BVF Shares.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>11</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
ARTICLE&nbsp;VIII&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
11</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>8.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Incorporation.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>11</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>8.02</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Authority.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>11</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>8.03</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>No Conflicts.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>11</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>8.04</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Governmental Approvals and Filings.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>11</FONT></TD>
</TR>
</TABLE>
<!-- insert table folio -->
<P ALIGN="CENTER"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=231524,FOLIO='1',FILE='DISK022:[03SAN6.03SAN1016]KI1016A.;5',USER='KLECK',CD='18-JAN-2003;06:24' -->
<A NAME="page_ki1016_1_2"> </A>
<!-- end of table folio -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
ARTICLE&nbsp;IX&nbsp;&nbsp;&nbsp;&nbsp;GENERAL PROVISIONS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
12</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.01</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Publicity.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>12</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.02</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Amendment and Waiver.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>12</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.03</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Notices.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>12</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.04</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Entire Agreement.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.05</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>No Third Party Beneficiary.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.06</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>No Assignment; Binding Effect.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.07</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Specific Performance; Legal Fees.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.08</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Headings.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.09</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Invalid Provisions.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.10</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Governing Law.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.11</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Consent to Jurisdiction and Service of Process.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>14</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>9.12</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="82%" VALIGN="TOP"><FONT SIZE=2>Counterparts.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>14</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ki1016_schedules"> </A>
<A NAME="toc_ki1016_3"> </A>
<BR></FONT><FONT SIZE=2><B>SCHEDULES    <BR>  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>Schedule&nbsp;I</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Common Stock Beneficially Owned by the Stockholders</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ki1016_exhibits"> </A>
<A NAME="toc_ki1016_4"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBITS    <BR>  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%"><FONT SIZE=2>Exhibit&nbsp;A</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2>Confidentiality Agreement</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%"><FONT SIZE=2>Exhibit&nbsp;B</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2>Bylaw Amendments</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>ii</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=940370,FOLIO='2',FILE='DISK022:[03SAN6.03SAN1016]KI1016A.;5',USER='KLECK',CD='18-JAN-2003;06:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This STOCKHOLDERS AGREEMENT dated as of January&nbsp;17, 2003 (this "</FONT><FONT SIZE=2><I>Stockholders Agreement</I></FONT><FONT SIZE=2>") is made and entered into by and among
Arena Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the "</FONT><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2>"), and Biotechnology Value Fund,&nbsp;L.P., a Delaware limited partnership,
Biotechnology Value Fund II,&nbsp;L.P., a Delaware limited partnership, BVF Investments,&nbsp;L.L.C., a Delaware limited liability company, BVF Partners&nbsp;L.P., a Delaware limited
partnership, and BVF&nbsp;Inc., a Delaware corporation ("</FONT><FONT SIZE=2><I>BVF</I></FONT><FONT SIZE=2>"), and Investment&nbsp;10,&nbsp;L.L.C., an Illinois limited liability company (each a
"</FONT><FONT SIZE=2><I>Stockholder</I></FONT><FONT SIZE=2>" and, collectively, the "</FONT><FONT SIZE=2><I>Stockholders</I></FONT><FONT SIZE=2>"). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
each Stockholder is the beneficial owner of the number of shares of common stock, par value $.0001 per share, of the Company (the "</FONT><FONT SIZE=2><I>Common
Stock</I></FONT><FONT SIZE=2>"), listed next to such Stockholder's name on </FONT><FONT SIZE=2><I>Schedule&nbsp;I </I></FONT><FONT SIZE=2>hereto (the "</FONT><FONT SIZE=2><I>BVF
Shares</I></FONT><FONT SIZE=2>"); and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
the Stockholders and the Company wish to provide for representation on the Board of Directors of the Company (the "</FONT><FONT SIZE=2><I>Board of
Directors</I></FONT><FONT SIZE=2>") for the Stockholders, certain restrictions on the sale and voting of the Common Stock beneficially owned by the Stockholders, the granting of certain rights to the
parties with respect to the purchase and sale of such Common Stock and the calling and noticing of meetings of stockholders, all as hereinafter set forth. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth in this Stockholders Agreement, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kk1016_article_i_definitions"> </A>
<A NAME="toc_kk1016_1"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;I    <BR>    <BR>    DEFINITIONS    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as otherwise specifically indicated, the following terms have the following
meanings for all purposes of this Stockholders Agreement: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Affiliate</I></FONT><FONT SIZE=2>" has the meaning assigned thereto in Rule&nbsp;12b-2 promulgated under the Exchange Act. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>beneficially owns</I></FONT><FONT SIZE=2>" (or comparable variations thereof) has the meaning set forth in Rule&nbsp;13d-3 promulgated under the
Exchange Act. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>BVF Designee</I></FONT><FONT SIZE=2>" means the individual designated from time to time by the Stockholders in a written notice delivered to the Company to serve
on the Board of Directors in accordance with the terms of this Stockholders Agreement, who initially shall be Mark&nbsp;N. Lampert. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>BVF Observer</I></FONT><FONT SIZE=2>" means the individual designated from time to time by the Stockholders in a written notice delivered to the Company to act
as a non-voting observer of meetings of the Board of Directors or committees thereof in accordance with the terms of this Stockholders Agreement, who initially shall be Matt Perry. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Bylaw Amendments</I></FONT><FONT SIZE=2>" has the meaning ascribed to it in </FONT><FONT SIZE=2><I>Section&nbsp;5.03(c)</I></FONT><FONT SIZE=2>. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Bylaws</I></FONT><FONT SIZE=2>" means the Amended and Restated By-Laws of the Company, as the same may be amended and restated from time to time. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Certificate of Incorporation</I></FONT><FONT SIZE=2>" means the Fifth Amended and Restated Certificate of Incorporation of the Company, as the same may be
amended and restated from time to time. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Commission</I></FONT><FONT SIZE=2>" means the Securities and Exchange Commission. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Confidentiality Agreement</I></FONT><FONT SIZE=2>" shall have the meaning ascribed to it in </FONT><FONT SIZE=2><I>Section&nbsp;5.01</I></FONT><FONT SIZE=2>. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>DGCL</I></FONT><FONT SIZE=2>" means the General Corporation Law of the State of Delaware, as amended. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Director Termination Date</I></FONT><FONT SIZE=2>" means the earliest of (i)&nbsp;the first date on which (w)&nbsp;the Company duly notices such Special
Meeting after a member of the Restricted Group gives notice to the Company of the exercise of its right to call a Special Meeting, (x)&nbsp;any member of the Restricted Group engages in any of the
activities prohibited by </FONT><FONT SIZE=2><I>Article&nbsp;IV </I></FONT><FONT SIZE=2>if such violation is not wholly cured </FONT></P>

</UL>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=4,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=178872,FOLIO='blank',FILE='DISK022:[03SAN6.03SAN1016]KK1016A.;5',USER='TCHAN',CD='18-JAN-2003;05:28' -->
<A NAME="page_kk1016_1_2"> </A>
<UL>
<BR>

<P><FONT SIZE=2>
within two (2)&nbsp;business days following notice thereof by the Company, (y)&nbsp;any member of the Restricted Group engages in a Schedule&nbsp;13D Transaction, or (z)&nbsp;the filing of an
amendment to the Schedule&nbsp;13D previously filed by the Stockholders with the Commission indicating that any member of the Restricted Group has a plan or proposal to engage in, or that it has
engaged in, a Schedule&nbsp;13D Transaction (other than an amendment filed following the execution and delivery of this Stockholders Agreement announcing such execution and delivery or subsequent
filings necessitated by the terms of this Agreement and actions by the parties hereunder); provided that the foregoing prohibition shall not impair or affect the exercise by the BVF Designee of his or
her fiduciary duties as a director of the Company in his or her capacity as such or prohibit filings required by law as a consequence thereof; (ii)&nbsp;if the Standstill Termination Date is
extended beyond October&nbsp;31, 2003 as a result of the delivery of an Initial Offer Notice by the Company, the Standstill Termination Date (but without giving effect to any extension of the
Standstill Termination Date as a result of the BVF Designee's failure to resign from the Board of Directors pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;2.01(f)</I></FONT><FONT SIZE=2>);
(iii)&nbsp;the expiration of the thirty (30)&nbsp;day period referred to in the second sentence of </FONT><FONT SIZE=2><I>Section&nbsp;2.01(e) </I></FONT><FONT SIZE=2>if, during such period,
BVF shall not have proposed a successor BVF Designee who BVF believes in good faith would qualify as an Independent Director; or (iv)&nbsp;the first date on which the members of the Restricted Group
beneficially own Voting Securities representing less than 25% of the Voting Securities beneficially owned by the members of the Restricted Group on the date hereof (after giving effect to any stock
dividends, stock splits and similar transactions involving the Common Stock). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Equity Securities</I></FONT><FONT SIZE=2>" means Voting Securities, Convertible Securities and Rights to Purchase Voting Securities. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Exchange Act</I></FONT><FONT SIZE=2>" means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Governmental or Regulatory Authority</I></FONT><FONT SIZE=2>" means any court, tribunal, arbitrator, authority, agency, commission, official or other
instrumentality of the United States, any foreign country or any domestic or foreign state, county, city or other political subdivision, or any stock exchange or market in which the Common Stock is
listed for trading or traded. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Independent Director</I></FONT><FONT SIZE=2>" means any member of the Board of Directors who is not excluded from qualification as an independent director (for
all purposes other than service on the Company's audit or compensation committees) by the enumerated </FONT><FONT SIZE=2><I>per se</I></FONT><FONT SIZE=2> exclusions from such qualification contained
in the listing requirements of the principal stock exchange or securities market on which the Common Stock is listed or traded at a time when the Company is required to have a Board of Directors
comprised of a majority of independent directors by such exchange or market (i.e., for purposes of this agreement, a
member of the Board of Directors shall not be disqualified as an Independent Director based upon a subjective determination by the Board of Directors unless such finding is based upon an enumerated </FONT> <FONT SIZE=2><I>per se</I></FONT><FONT
SIZE=2> exclusion from qualification as an independent director). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Liens</I></FONT><FONT SIZE=2>" means any lien, claim, mortgage, encumbrance, pledge, security interest, equity or charge of any kind, other than restrictions
arising under federal or state securities laws. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Market Value</I></FONT><FONT SIZE=2>" means the greater of (i)&nbsp;the closing price per share of the Common Stock on the principal trading market on which
the Common Stock is traded on the day an Initial Offer Notice is delivered by the Company to the Restricted Group (or if such day is not a trading day, on the immediately preceding trading day) or
(ii)&nbsp;the trailing average of the closing prices per share of the Common Stock on such principal trading market for the twenty (20)&nbsp;trading days ending on, and including, the day an
Initial Offer Notice is delivered by the Company to the Restricted Group (or if such day is not a trading day, on the immediately preceding trading day). </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=5,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=339698,FOLIO='2',FILE='DISK022:[03SAN6.03SAN1016]KK1016A.;5',USER='TCHAN',CD='18-JAN-2003;05:28' -->
<A NAME="page_kk1016_1_3"> </A>
<UL>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Person</I></FONT><FONT SIZE=2>" means any individual, corporation, limited liability company, partnership, trust, other entity or group (within the meaning of
Section&nbsp;13(d)(3) of the Exchange Act). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Representatives</I></FONT><FONT SIZE=2>" of any Person means such Person's directors, officers, employees, legal, investment banking and financial advisors,
accountants and any other agents and representatives of such entity. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Restricted Group</I></FONT><FONT SIZE=2>" means, collectively, (i)&nbsp;each Stockholder, (ii)&nbsp;any and all Affiliates of any Stockholder,
(iii)&nbsp;the then current officers and directors of any Stockholder or any Affiliate of any Stockholder, (iv)&nbsp;with respect to any Stockholder who is an individual, (a)&nbsp;any and all
immediate family members of such Stockholder, (b)&nbsp;the heirs, executors, personal representatives and administrators of any of the foregoing persons, (c)&nbsp;any and all trusts established
for the benefit of any of the foregoing persons and (d)&nbsp;any and all charitable foundations established by any of the foregoing persons, and (v)&nbsp;the other members of any and all groups
(within the meaning of Section&nbsp;13(d)(3) of the Exchange Act) of which any Stockholder or any Affiliate of such Stockholder is a member. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Rights Plan</I></FONT><FONT SIZE=2>" means the rights agreement dated as of October&nbsp;30, 2002 between the Company and Computershare Trust
Company,&nbsp;Inc., as rights agent, as the same may be amended from time to time, and "</FONT><FONT SIZE=2><I>Rights</I></FONT><FONT SIZE=2>" has the meaning given such term in the Rights
Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Schedule&nbsp;13D Transaction</I></FONT><FONT SIZE=2>" means any action or transaction described in any of paragraphs&nbsp;(a) through (j) of Item&nbsp;4
of Schedule&nbsp;13D promulgated by the Commission with respect to the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Special Meeting</I></FONT><FONT SIZE=2>" means a special meeting of the stockholders of the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Standstill Period</I></FONT><FONT SIZE=2>" means the period from the date of this Stockholders Agreement through the Standstill Termination Date. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Standstill Termination Date</I></FONT><FONT SIZE=2>" means October&nbsp;31, 2003, unless the Company delivers an Initial Offer Notice in which case
"</FONT><FONT SIZE=2><I>Standstill Termination Date</I></FONT><FONT SIZE=2>" means December&nbsp;31, 2003; </FONT><FONT SIZE=2><I>provided </I></FONT><FONT SIZE=2>that (A)&nbsp;if the Company
delivers an Initial Offer Notice and either (i)&nbsp;the Restricted Group accepts the terms of an Offer Notice or (ii)&nbsp;the Restricted Group rejects the terms of an Offer Notice offering a
price per share of Common Stock equal to or exceeding the Threshold Amount, in either case pursuant to </FONT><FONT SIZE=2><I>Article&nbsp;VI</I></FONT><FONT SIZE=2>,
"</FONT><FONT SIZE=2><I>Standstill Termination Date</I></FONT><FONT SIZE=2>" means the earlier of (x)&nbsp;December&nbsp;31, 2004 or (y)&nbsp;the first date on which the members of the
Restricted Group beneficially own Voting Securities representing less than 25% of the Voting Securities beneficially owned by the members of the Restricted Group on the date hereof (after giving
effect to any stock dividends, stock splits and similar transactions involving the Common Stock); and (B)&nbsp;if the Company fails to close on a transaction pursuant to </FONT> <FONT SIZE=2><I>Section&nbsp;6.01 </I></FONT><FONT SIZE=2>for any reason
other than the Restricted Group's declination of an offer thereunder, "</FONT><FONT SIZE=2><I>Standstill Termination
Date</I></FONT><FONT SIZE=2>" means October&nbsp;31, 2003; </FONT><FONT SIZE=2><I>provided further</I></FONT><FONT SIZE=2>, that if the BVF Designee shall not have resigned from the Board of
Directors as required under </FONT><FONT SIZE=2><I>Section&nbsp;2.01(f)</I></FONT><FONT SIZE=2>, the Standstill Termination Date shall be extended until the date of such resignation. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Subsidiary</I></FONT><FONT SIZE=2>" means any Person in which the Company directly or indirectly through Subsidiaries or otherwise beneficially owns more than
fifty percent (50%) of either the equity interests in, or securities having the power generally to vote for the election of directors of, such Person. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Threshold Amount</I></FONT><FONT SIZE=2>" means $8.00, subject to proportionate adjustment in the event of a stock dividend, stock split or similar transaction
involving the Common Stock. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>2003 Annual Meeting</I></FONT><FONT SIZE=2>" means the 2003 annual meeting of the stockholders of the Company, or any adjournment or postponement thereof. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=6,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=513576,FOLIO='3',FILE='DISK022:[03SAN6.03SAN1016]KK1016A.;5',USER='TCHAN',CD='18-JAN-2003;05:28' -->
<A NAME="page_kk1016_1_4"> </A>
<UL>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Voting Securities</I></FONT><FONT SIZE=2>" means the Common Stock and any other securities of the Company of any kind or class having the power generally to vote
for the election of directors; "</FONT><FONT SIZE=2><I>Convertible Securities</I></FONT><FONT SIZE=2>" means securities of the Company which are convertible or exchangeable (whether presently
convertible or exchangeable or not) into Voting Securities; "</FONT><FONT SIZE=2><I>Rights to Purchase Voting Securities</I></FONT><FONT SIZE=2>" means options and rights issued by the Company
(whether presently exercisable or not) to purchase Voting Securities or Convertible Voting Securities (but not including the Rights); and "</FONT><FONT SIZE=2><I>Outstanding Voting
Securities</I></FONT><FONT SIZE=2>" means
at any time the then issued and outstanding Voting Securities (not including shares issuable upon the conversion of any Convertible Securities or upon the exercise of any Rights to Purchase Voting
Securities). </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;In
addition, the following terms are defined in the Sections set forth below: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="63%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Board of Directors"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Preamble</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Business Combination"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Section&nbsp;4.02</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"BVF"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Preamble</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"BVF Shares"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Preamble</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Common Stock"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Preamble</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Company"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Preamble</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Initial Offer Notice"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Section&nbsp;6.01(a)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Offer Notices"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Section&nbsp;6.01(b)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Second Offer Notice"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Section&nbsp;6.01(b)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Stockholder"&nbsp;and&nbsp;"Stockholders"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Preamble</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="58%"><FONT SIZE=2>"Stockholders Agreement"</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&#151;Preamble</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;Unless
the context of this Stockholders Agreement otherwise requires, (i)&nbsp;words of any gender include each other gender; (ii)&nbsp;words using the singular or
plural number also include the plural or singular number, respectively; (iii)&nbsp;the terms "hereof," "herein," "hereby" and derivative or similar words refer to this entire Stockholders Agreement;
(iv)&nbsp;the terms "Article" or "Section" refer to the specified Article or Section of this Stockholders Agreement and (v)&nbsp;all references to statutes, rules and regulations are to the
enumerated statutes, rules and regulations and any successor statute, rule or regulation. Whenever this Stockholders Agreement refers to a number of days, such number shall refer to calendar days
unless business or trading days are specified. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kk1016_article_ii_board_of_directors"> </A>
<A NAME="toc_kk1016_2"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;II    <BR>    <BR>    BOARD OF DIRECTORS    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Composition of Board of Directors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;On the date hereof, the Board of Directors has, pursuant to
the powers granted to it under the Bylaws, increased the size of the Board of Directors by one and elected the BVF Designee to fill the vacancy so created on the Board of Directors, to serve in such
capacity from the date hereof through the earlier of (i)&nbsp;the 2003 Annual Meeting, and until his successor shall have been duly appointed and qualified, or (ii)&nbsp;the Director Termination
Date. The BVF Designee also has been appointed by the Board of Directors to serve on the Nominating Committee and the Corporate Governance Committee. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;Until
the Director Termination Date, the Board of Directors shall, at each meeting of stockholders of the Company at which the term of the BVF Designee is scheduled to
expire, nominate the BVF Designee to stand for election as a director of the Company for a succeeding term in accordance with the Company's procedures for nomination of directors as provided for in
its Bylaws, for election, recommend such election and solicit proxies in respect thereof and vote the shares of Common Stock represented by all proxies granted by stockholders in connection with the
solicitation of proxies by the Board of Directors in connection with such meeting in favor of the BVF Designee, </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=7,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=189774,FOLIO='4',FILE='DISK022:[03SAN6.03SAN1016]KK1016A.;5',USER='TCHAN',CD='18-JAN-2003;05:28' -->
<A NAME="page_kk1016_1_5"> </A>
<BR>

<P><FONT SIZE=2>
except for such proxies that specifically indicate a vote to withhold authority with respect to the BVF Designee. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;Until
the Director Termination Date, but subject to the provisions of paragraph&nbsp;(e) of this </FONT><FONT SIZE=2><I>Section&nbsp;2.01</I></FONT><FONT SIZE=2>,
the Board of Directors shall cause any vacancy created on the Board of Directors by reason of the death, resignation or removal of the then serving BVF Designee to be filled by the successor BVF
Designee named by the Stockholders. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;While
serving on the Board of Directors and any committee thereof, the BVF Designee shall be entitled to all the rights and privileges and subject to all the obligations
of the other directors and committee members; </FONT><FONT SIZE=2><I>provided </I></FONT><FONT SIZE=2>that the BVF Designee shall not be entitled to (i)&nbsp;participate in or observe, and shall
upon the good faith request of the Board of Directors or any such committee recuse himself from, any meeting or portion thereof at which the Board of Directors or any such committee is evaluating
and/or taking action with respect to (x)&nbsp;the ownership of Voting Securities by any member of the Restricted Group, (y)&nbsp;the exercise of any of the Company's rights or enforcement of any
of the obligations of any member of the Restricted Group under this Stockholders Agreement (including, without limitation, the exercise by the Company of its right to purchase Common Stock of the
Restricted Group pursuant to </FONT><FONT SIZE=2><I>Article&nbsp;VI</I></FONT><FONT SIZE=2>) or (z)&nbsp;any transaction proposed by, or with, any member of the
Restricted Group; or (ii)&nbsp;receive any compensation payable to directors for service on the Board of Directors and/or any committee thereof, including the grant or award of any Equity
Securities; </FONT><FONT SIZE=2><I>provided </I></FONT><FONT SIZE=2>that the BVF Designee shall be entitled to reimbursement of reasonable travel expenses and coverage under the Company's directors'
and officers' insurance policy to the same extent provided generally to the members of the Board of Directors who are not also officers of the Company in accordance with the Company's policies. The
Board of Directors or any such committee shall be entitled to take such actions as it shall deem reasonably necessary or appropriate to carry out the provisions of the preceding sentence. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;The
Stockholders shall use reasonable best efforts to insure that the BVF Designee shall at all times be an Independent Director. If (x)&nbsp;the BVF Designee shall
not meet the definition of an Independent Director hereunder and (y)&nbsp;the Board of Directors does not at the time, or will not within thirty (30)&nbsp;days, satisfy the listing requirements of
the principal stock exchange or securities market on which the Common Stock is then listed or traded because the Board of Directors does not consist of a majority of Independent Directors, written
notice of such determination shall be given to BVF, which shall during the thirty (30)&nbsp;day period following such notification name a new BVF Designee who BVF in good faith believes would
qualify as an Independent Director; </FONT><FONT SIZE=2><I>provided </I></FONT><FONT SIZE=2>that BVF shall be deemed not to have acted in good faith for this purpose if, among other reasons, the
proposed successor BVF Designee (i)&nbsp;has not agreed to serve as the BVF Designee or (ii)&nbsp;does not qualify as an Independent Director for a similar reason that the incumbent BVF Designee
fails to qualify as an Independent Director. If the Stockholders and the Board of Directors agree on a successor BVF Designee in accordance with the preceding sentence, the Stockholders shall cause
the incumbent BVF Designee to resign from the Board of Directors and the successor BVF Designee shall be elected to the Board of Directors in accordance with paragraph&nbsp;(c) of this </FONT> <FONT SIZE=2><I>Section&nbsp;2.01</I></FONT><FONT
SIZE=2>. If the Board of Directors determines that the successor BVF Designee proposed by BVF in good faith does not qualify as an
Independent Director, the Board of Directors shall be entitled to increase the size of the Board of Directors to nine (9)&nbsp;directors and elect two new directors who it determines do qualify as
Independent Directors. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;The
Stockholders shall no longer be entitled to have the BVF Designee serve on the Board of Directors from and after the Director Termination Date, at which time the
Stockholders will cause the BVF Designee immediately to resign from the Board of Directors. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.02</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Board Committees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors shall at all times cause the BVF Designee to be a member of the
Nominating Committee, the Corporate Governance Committee and each other committee of the Board of Directors on which any officer of the Company is then serving as a </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=8,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=457216,FOLIO='5',FILE='DISK022:[03SAN6.03SAN1016]KK1016A.;5',USER='TCHAN',CD='18-JAN-2003;05:28' -->
<A NAME="page_kk1016_1_6"> </A>
<BR>

<P><FONT SIZE=2>
member; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that the BVF Designee shall not be entitled to be (i)&nbsp;a member of any committee (but shall be entitled to act as an observer in
the same manner as the BVF Observer) all of whose members are required by the then applicable rules of the principal stock exchange or securities market on which the Common Stock is listed or traded
to be an Independent Director unless such BVF Designee has been determined to be an Independent Director; or (ii)&nbsp;a member of any committee formed exclusively for the purpose of evaluating
and/or taking action with respect to (x)&nbsp;the ownership of Voting Securities by any member of the Restricted Group, (y)&nbsp;the exercise of any of the Company's rights or enforcement of any
of the obligations of any member of the Restricted Group under this Stockholders Agreement (including, without limitation, the exercise by the Company of its right to
purchase Common Stock of the Restricted Group pursuant to </FONT><FONT SIZE=2><I>Article&nbsp;VI) </I></FONT><FONT SIZE=2>or (z)&nbsp;any transaction proposed by, or with, any member of the
Restricted Group. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.03</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;BVF Observer.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The BVF Observer shall be entitled to serve as a non-voting observer of and
participant in any meeting (or portion thereof) of the Board of Directors or any committee thereof whose meetings the BVF Designee is permitted by the terms of this Stockholders Agreement to attend.
The Board of Directors shall cause all notices sent and other materials delivered or provided to directors in connection with any meeting of the Board of Directors or any committee thereof which the
BVF Observer is entitled to attend to be sent, delivered or provided, as the case may be, to the BVF Observer by the same method of delivery as used for the directors. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.04</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Information About BVF Designee and BVF Observer.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;BVF shall promptly provide to the Company, as the Company
may from time to time reasonably request, information regarding the BVF Designee or the BVF Observer for purposes of determining whether the BVF Designee is an Independent Director or for inclusion in
any form, report, schedule, registration statement, definitive proxy statement or other documents required to be filed by the Company with the Commission or any other Governmental or Regulatory
Authority. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.05</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Compliance with Board Policies.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;It shall be a precondition to the right of the initial BVF Designee and the
initial BVF Observer, and their respective successors, to attend any meeting of the Board of Directors or committee thereof that such individual shall have agreed to abide by the established policies
of the Board of Directors and the committees thereof generally applicable to all directors or committee members that are in effect from time to time. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kk1016_article_iii_transfer_and_voting_of_shares"> </A>
<A NAME="toc_kk1016_3"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;III    <BR>    <BR>    TRANSFER AND VOTING OF SHARES    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restriction on Certain Transfers.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Until the Standstill Termination Date, no member of the Restricted Group
shall, directly or indirectly, transfer beneficial ownership of any shares of Common Stock to any Person to the extent such transfer would cause the Rights to become exercisable or the transferee to
be an "Acquiring Person" under the Rights Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.02</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Voting of Shares by the Restricted Group.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Until the Director Termination Date, at each meeting
of stockholders of the Company held for the purpose of electing any member of the Board of Directors, the Stockholders shall cause all Voting Securities beneficially owned by any member of the
Restricted Group to be present at such meeting for purposes of establishing a quorum and to be voted (x)&nbsp;for the
nominees recommended by the Board of Directors (provided such nominees include the BVF Designee), (y)&nbsp;on all other proposals of the Board of Directors and any proposals by other stockholders of
the Company not covered by clause&nbsp;(z) below, as such member of the Restricted Group determines is appropriate, and (z)&nbsp;on any proposals of any other stockholder of the Company who is
also proposing one or more nominees for election as director in opposition to the nominees of the Board of Directors at any such meeting, in accordance with the recommendation of the Board of
Directors. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=9,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=554286,FOLIO='6',FILE='DISK022:[03SAN6.03SAN1016]KK1016A.;5',USER='TCHAN',CD='18-JAN-2003;05:28' -->
<A NAME="page_kk1016_1_7"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;If
the Company does not receive at least five (5)&nbsp;business days prior to such meeting a duly executed proxy card or cards from a Stockholder irrevocably directing
that its Voting Securities be voted at such meeting in accordance with the terms of </FONT><FONT SIZE=2><I>Section&nbsp;3.02(a)</I></FONT><FONT SIZE=2>, such Stockholder hereby irrevocably (to the
fullest extend provided by law) appoints each of the then serving Chief Executive Officer and General Counsel of the Company, and each of them, as the attorney-in-fact and
proxy of such Stockholder or other member of the Restricted Group, with full power of substitution and resubstitution, to the full extent of such Stockholder's or other member of the Restricted
Group's rights with respect to any shares of Common Stock owned by them, beneficially or of record, to vote such shares of Common Stock, at any annual or special meeting of the stockholders of the
Company held prior to the Director Termination Date, in accordance with clause&nbsp;(x) and (z) of the preceding sentence. The proxy granted in the previous sentence is irrevocable to the fullest
extent provided by law, coupled with an interest and granted as an inducement to the Company for entering into this Stockholders Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kk1016_article_iv_standstill"> </A>
<A NAME="toc_kk1016_4"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;IV    <BR>    <BR>    STANDSTILL    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Limitation on Acquisition of Equity Securities.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof through the Standstill Termination
Date, no member of the Restricted Group shall, directly or indirectly, purchase or acquire, or make any offer to or agree to purchase or acquire, beneficial ownership of any Equity Securities, except
(i)&nbsp;by way of stock dividends, stock splits or other distributions or offerings made available to holders of Equity Securities generally, or (ii)&nbsp;transfers of shares of Common Stock
beneficially owned by any Stockholder on the date hereof among members of the Restricted Group, provided in the case of clause&nbsp;(ii)&nbsp;any transferee first agrees in writing to be bound by
the terms of this Stockholders Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.02</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Standstill.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof through the Standstill Termination Date, no member of the Restricted Group
will, directly or indirectly, (i)&nbsp;acquire or agree, offer, seek or propose (whether publicly or otherwise) to acquire ownership (including but not limited to beneficial ownership) of any
substantial portion of the assets or Equity Securities of the Company, whether by means of a
negotiated purchase of assets, tender or exchange offer, merger or other business combination, recapitalization, restructuring or other extraordinary transaction (a "</FONT><FONT SIZE=2><I>Business
Combination</I></FONT><FONT SIZE=2>"), (ii)&nbsp;engage in any "solicitation" of "proxies" (as such terms are used in the proxy rules promulgated under the Exchange Act, but disregarding
clause&nbsp;(iv) of Rule&nbsp;14a-1(l)(2) but including any exempt solicitation pursuant to Rule&nbsp;14a-2(b)(1) or (2)), submit any proposal (including nominations of
director candidates, except as provided in </FONT><FONT SIZE=2><I>Section&nbsp;2.01</I></FONT><FONT SIZE=2>) for consideration at any annual or special meeting of the stockholders of the Company
(including pursuant to Rule&nbsp;14a-8 promulgated under the Exchange Act), (iii)&nbsp;form, join or in any way participate in a "group" (as defined in Section&nbsp;13(d)(3) of the
Exchange Act) with respect to any Equity Securities which proposes to take any action or enter into any transaction that is prohibited by this Section or any other provision of this Stockholders
Agreement, nor will they provide any financing to any such group for any such purpose, or (iv)&nbsp;engage in any Schedule&nbsp;13D Transaction or file any amendment to the Schedule&nbsp;13D
previously filed by the Stockholders with the Commission indicating that any member of the Restricted Group has a plan or proposal to engage in, or that it has engaged in, a Schedule&nbsp;13D
Transaction (other than an amendment filed following the execution and delivery of this Stockholders Agreement announcing such execution and delivery or subsequent filings necessitated by the terms of
this Agreement and actions by the parties hereunder); </FONT><FONT SIZE=2><I>provided </I></FONT><FONT SIZE=2>that the foregoing prohibition shall not impair or affect the exercise by the BVF
Designee of his or her fiduciary duties as a director of the Company in his or her capacity as such or prohibit filings required by law as a consequence thereof. In the event that any member of the
Restricted Group is approached by any third party to enter into any discussions, negotiations, agreements, arrangements or understandings with respect to any of the foregoing, such member of the
Restricted Group shall advise such third party of its obligations under this </FONT><FONT SIZE=2><I>Section&nbsp;4.02</I></FONT><FONT SIZE=2>. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=10,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=552028,FOLIO='7',FILE='DISK022:[03SAN6.03SAN1016]KK1016A.;5',USER='TCHAN',CD='18-JAN-2003;05:28' -->
<BR>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_km1016_1_8"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="km1016_article_v_other_agreements"> </A>
<A NAME="toc_km1016_1"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;V    <BR>    <BR>    OTHER AGREEMENTS    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality Agreement.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Simultaneously with the execution and delivery of this Stockholders Agreement,
the Company and each of the Stockholders are executing and delivering to the Company the confidentiality agreement in the form of </FONT><FONT SIZE=2><I>Exhibit&nbsp;A  </I></FONT><FONT SIZE=2>hereto (the "</FONT><FONT SIZE=2><I>Confidentiality
Agreement</I></FONT><FONT SIZE=2>"). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.02</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Solicitation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof through the first anniversary of the Director Termination Date, no
member of the Restricted Group will, directly or indirectly, on its own behalf or on the behalf of any other Person, solicit to employ any officer or employee of the Company or any of its
Subsidiaries, so long as they are employed by the Company or any of its Subsidiaries or had been so employed during the prior six (6)&nbsp;months, without obtaining the prior written consent of the
Company. The term "solicit to employ" does not include general solicitations of employment not specifically directed towards employees of the Company or any of its Subsidiaries. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.03</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Right to Call a Meeting of Company Stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In the event that the Company does not
(i)&nbsp;on or prior to May&nbsp;15<SUP>th</SUP> of any calendar year during the Standstill Period and in the first calendar year following the Standstill Termination Date (or, if the
Standstill Termination Date occurs before the date of the annual meeting of stockholders for such year, then in the calendar year in which the Standstill Termination Date occurs), give notice to
stockholders of the calling of its annual meeting of stockholders (including all business noticed therefor) to be held on or before June&nbsp;30<SUP>th</SUP> of such calendar year or
(ii)&nbsp;conduct its annual meeting of stockholders on or before June&nbsp;30<SUP>th</SUP> of any such calendar year, BVF shall (A)&nbsp;in the case of any failure arising under
clause&nbsp;(i), have the right to require the Company to call such annual meeting by delivering notice thereof to the Company and, within five (5)&nbsp;business days following receipt by the
Company of such notice from BVF, the Company shall cause the corporate Secretary to call and give notice of such annual meeting for a date not less than forty-five (45)&nbsp;nor more
than sixty (60)&nbsp;days following the giving of notice by the corporate Secretary to the stockholders of the Company in the manner contemplated by the Bylaws, and such annual meeting will be held
in accordance with such notice, and (B)&nbsp;in the case of any failure arising under clause&nbsp;(ii), if such meeting can no longer be held, have the immediate right to require the calling of a
Special Meeting, and the Company shall respond thereto as provided in the second sentence of </FONT><FONT SIZE=2><I>Section&nbsp;5.03(b)</I></FONT><FONT SIZE=2>. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;(i)&nbsp;Unless
the Company shall have delivered an Initial Offer Notice in accordance with </FONT><FONT SIZE=2><I>Section&nbsp;6.01 </I></FONT><FONT SIZE=2>on or
before October&nbsp;15, 2003, or (ii)&nbsp;if such notice was accepted by BVF and the Company fails to close such transaction as required by </FONT> <FONT SIZE=2><I>Section&nbsp;6.01(c)</I></FONT><FONT SIZE=2>, BVF shall thereafter have the right to
require the Company to hold a Special Meeting by delivering, at any time on or after
November&nbsp;1, 2003 and prior to February&nbsp;1, 2004, notice thereof to the Company. Within five (5)&nbsp;business days following receipt by the Company of such notice from BVF, the Company
shall cause the corporate Secretary to call and give notice of a Special Meeting for a date not less than forty-five (45)&nbsp;nor more than sixty (60)&nbsp;days following the giving
of notice by the corporate Secretary to the stockholders of the Company in the manner contemplated by the Bylaws, and the Special Meeting will be held in accordance with such notice. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;Concurrently
with the execution and delivery of this Stockholders Agreement, the Board of Directors has adopted the amendments to the Bylaws in the form of </FONT> <FONT SIZE=2><I>Exhibit&nbsp;B </I></FONT><FONT SIZE=2>hereto (the "</FONT><FONT SIZE=2><I>Bylaw
Amendments</I></FONT><FONT SIZE=2>"), effective immediately, to provide (i)&nbsp;for BVF's
right to require the Company to call an annual or special meeting of the stockholders of the Company consistent with the provisions of paragraphs&nbsp;(a) and (b) of this </FONT> <FONT SIZE=2><I>Section&nbsp;5.03 </I></FONT><FONT SIZE=2>and
(ii)&nbsp;that nominations by stockholders of directors for election at any annual or special meeting of stockholders of the
Company held during the Standstill Period or at the annual meeting of stockholders of the Company held in the first calendar year following the Standstill Period shall in no event be required on a
date earlier than forty-five (45)&nbsp;days </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=11,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=551725,FOLIO='8',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_9"> </A>
<BR>

<P><FONT SIZE=2>
after the giving of notice of the date of any such annual or special meeting. For so long as BVF has the right to require the Company to call an annual or special meeting of the stockholders of the
Company pursuant to this Stockholders Agreement, the Board of Directors will not amend any provision of the Bylaws added by the Bylaw Amendments, or adopt any Bylaw provision inconsistent therewith. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;In
connection with any meeting of stockholders which is the subject of </FONT><FONT SIZE=2><I>Section&nbsp;5.03</I></FONT><FONT SIZE=2>, the Company shall not adjourn
any such meeting to a date later than five (5)&nbsp;business days after such adjournment absent (i)&nbsp;an order of a court of competent jurisdiction to such effect or (ii)&nbsp;the failure to
obtain a quorum at such meeting. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.04</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Access to Information.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;From the date hereof through the Director Termination Date, (a)&nbsp;the Company
will provide the BVF Designee and the BVF Observer with access, during normal business hours of the Company, to all contracts, significant negotiations, budgets, business plans, internal projections,
offers or plans to acquire or license from others, or plans to dispose of or license to others, material products, business lines or any company, including the Company, and other information
reasonably requested, </FONT><FONT SIZE=2><I>provided </I></FONT><FONT SIZE=2>that the Company shall not be required to provide such access (i)&nbsp;at such a time or in such a manner as it
determines in good faith would be likely to unreasonably interfere with the Company's normal business operations or any proposed transactions or projects of the Company, or (ii)&nbsp;to any such
communications or information relating to the negotiation, execution or delivery of this Stockholders Agreement or to any matter referred to in clause&nbsp;(x), (y) or (z) of </FONT> <FONT SIZE=2><I>Section&nbsp;2.01(d)(i)</I></FONT><FONT SIZE=2>;
and (b)&nbsp;no member of the Restricted Group will contact any employee of the Company or any of its Subsidiaries
(including any of their scientists) who is not an "executive officer" of the Company as designated in the Company's then most recent Annual Report on Form&nbsp;10-K filed
with the Commission, other than (i)&nbsp;in connection with presentations to the Board of Directors or any committee thereof or to which the BVF Designee or the BVF Observer otherwise is invited, or
(ii)&nbsp;with the prior consent of any of the Company's "executive officers", who may impose such reasonable restrictions on such access as may be necessary to reasonably mitigate disruption of the
Company's business and operations. It is understood and agreed that any and all information obtained or reviewed by the BVF Designee or the BVF Observer pursuant to this Section shall be subject to
the terms of the Confidentiality Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.05</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;10b5-1 Program.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event that any member of the Restricted Group seeks to establish a
program providing for the sale of Common Stock pursuant to Rule&nbsp;10b5-1 of the Exchange Act, the Company shall, subject to applicable laws and regulations of any Governmental or
Regulatory Authority, consent to and provide such reasonable cooperation and assistance in the implementation of such program as such member of the Restricted Group may request, </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that
(i)&nbsp;the Company shall not unreasonably withhold its consent to any such request (including in any manner that would be
discriminatory among directors) and (ii)&nbsp;the Company shall in no event be required to make any public disclosures that it is not at the time otherwise prepared to make in connection with any
such request. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="km1016_article_vi_offer_rights"> </A>
<A NAME="toc_km1016_2"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;VI    <BR>    <BR>    OFFER RIGHTS    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Offer Right.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;From July&nbsp;1, 2003 through October&nbsp;15, 2003, the Company shall have
the right to offer to purchase from the members of the Restricted Group at least three million (3,000,000) shares of Common Stock at a cash purchase price per share representing a ten percent (10%)
discount to Market Value. If the Company elects to make the offer pursuant to the preceding sentence, the Company shall deliver a notice of such election (the "</FONT><FONT SIZE=2><I>Initial Offer
Notice</I></FONT><FONT SIZE=2>") to the Restricted Group. Upon delivery of the Initial Offer Notice, the offer contained therein shall be irrevocable until lapse of the two business-day
period referenced in the next sentence. The Restricted Group shall have two (2)&nbsp;business days following the date of delivery of the Initial Offer Notice in which to accept or reject the terms
of the Initial Offer Notice, provided that the Restricted Group shall only be required to sell </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=12,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=65278,FOLIO='9',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_10"> </A>

<P><FONT SIZE=2>
three million (3,000,000) shares of Common Stock pursuant to the terms of the Initial Offer Notice in order to be deemed to have accepted the Initial Offer Notice. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;If
the Restricted Group rejects the terms of the Initial Offer Notice (including by failing to accept such terms within such two (2)&nbsp;business day period), the
Company shall have the right during the ten (10)&nbsp;business day period thereafter to offer to purchase from the members of the Restricted Group at least three million (3,000,000) shares of Common
Stock at a price that is higher than the price offered in the Initial Offer Notice. If the Company elects to make the offer pursuant to the preceding sentence,
the Company shall deliver a notice of such election (the "</FONT><FONT SIZE=2><I>Second Offer Notice</I></FONT><FONT SIZE=2>" and, together with the Initial Offer Notice, the
"</FONT><FONT SIZE=2><I>Offer Notices</I></FONT><FONT SIZE=2>") to the Restricted Group. Upon delivery of the Second Offer Notice, the offer contained therein shall be irrevocable until lapse of the
two business-day period referenced in the next sentence. The Restricted Group shall have two (2)&nbsp;business days following the date of delivery of the Second Offer Notice in which to
accept or reject the terms of the Second Offer Notice; </FONT><FONT SIZE=2><I>provided </I></FONT><FONT SIZE=2>that the Restricted Group shall only be required to sell three million (3,000,000)
shares of Common Stock pursuant to the terms of the Second Offer Notice in order to be deemed to have accepted the Second Offer Notice, and </FONT><FONT SIZE=2><I>further provided  </I></FONT><FONT SIZE=2>that a failure by the Restricted Group to
accept such terms within such two (2)&nbsp;business day period shall be deemed a rejection of such terms. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;Any
acceptance by the Restricted Group of the terms of an Offer Notice shall be irrevocable. The closing of any purchase and sale of shares of Common Stock pursuant to
an Offer Notice shall take place at the principal executive offices of the Company at a price and on the date set forth in the applicable Offer Notice, which date shall not be later than two
(2)&nbsp;business days following the date of acceptance of such Offer Notice. At such closing, the Company (and/or the Company's designee or designees) shall deliver the purchase price for the
shares being purchased by wire transfer of immediately available funds to an account previously identified by BVF, against delivery of certificates representing the number of shares of Common Stock
being purchased, together with an instrument signed by or on behalf of each selling stockholder to the effect that such selling stockholder is the owner of the shares being sold, free and clear of all
Liens and restrictions, and that the sale has been authorized by all necessary corporate, partnership or limited liability company action, as the case may be, on the part of such selling stockholder. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;All
share amounts referred to in this Section shall be subject to proportionate adjustment in the event of a stock dividend, stock split or similar transaction involving
the Common Stock. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="km1016_article_vii_representations_an__art02571"> </A>
<A NAME="toc_km1016_3"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;VII    <BR>    <BR>    REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Stockholder hereby represents and warrants to the Company as follows: </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Authority.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Stockholders Agreement has been duly and validly executed and delivered by each Stockholder
and constitutes a legal, valid and binding obligation of such Stockholder enforceable against such Stockholder in accordance with its terms, except as enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors' rights generally and by general equitable principles (regardless of whether such enforceability is
considered in a proceeding in equity or at law). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.02</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Conflicts.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The execution and delivery by each Stockholder of this Stockholders Agreement do not, and the
performance by each Stockholder of such Stockholder's obligations under this Stockholders Agreement and the consummation of the transactions contemplated hereby will not: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;conflict
with or result in a violation or breach of any term or provision of any law, statute, rule or regulation or any order, judgment or decree of any Governmental or
Regulatory Authority applicable to such Stockholder or any of such Stockholder's properties or assets; or </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=13,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=706128,FOLIO='10',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_11"> </A>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;(i)&nbsp;conflict
with or result in a violation or breach of, (ii)&nbsp;constitute (with or without notice or lapse of time or both) a default under,
(iii)&nbsp;require such Stockholder to obtain any consent, approval or action of, make any filing with or give any notice to any Person as a result or under the terms of, or (iv)&nbsp;result in
the creation or imposition of any Lien upon any of such Stockholder's properties or assets under, any contract, agreement, plan, permit or license to which such Stockholder is a party. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.03</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governmental Approvals and Filings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No consent, approval or action of, filing with or notice to any
Governmental or Regulatory Authority on the part of any Stockholder is required in connection with the execution and delivery of this Stockholders Agreement, other than the filing with the Commission
referred to in the next Section. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.04</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;BVF Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except for the BVF Shares listed on </FONT><FONT SIZE=2><I>Schedule&nbsp;I  </I></FONT><FONT SIZE=2>hereto, the members of the Restricted Group do not
beneficially own any shares of Common Stock. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="km1016_article_viii_representa__km102450"> </A>
<A NAME="toc_km1016_4"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;VIII    <BR>    <BR>    REPRESENTATIONS AND WARRANTIES OF THE COMPANY    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company hereby represents and warrants to the Stockholders as follows: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Incorporation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company is a corporation duly incorporated, validly existing and in good standing under
the laws of the State of Delaware. The Company has the requisite corporate power and authority to execute and deliver this Stockholders Agreement, to perform its obligations hereunder and to
consummate the transactions contemplated hereby. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.02</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Authority.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The execution and delivery by the Company of this Stockholders Agreement, and the performance by
the Company of its obligations hereunder, have been duly and validly authorized by the Board of Directors, no other corporate action on the part of the Company or its stockholders being necessary.
This Stockholders Agreement has been duly and validly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company in accordance with its terms, except as
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors' rights generally and by general equitable principles
(regardless of whether such enforceability is considered in a proceeding in equity or at law). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.03</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Conflicts.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The execution and delivery by the Company of this Stockholders Agreement do not, and the
performance by the Company of its obligations under this Stockholders Agreement and the consummation of the transactions contemplated hereby will not: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;conflict
with or result in a violation or breach of any of the terms, conditions or provisions of the Certificate of Incorporation or Bylaws; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;conflict
with or result in a violation or breach of any term or provision of any law, statute, rule or regulation or any order, judgment or decree of any Governmental or
Regulatory Authority applicable to the Company or any of its properties or asset; or </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;(i)&nbsp;conflict
with or result in a violation or breach of, (ii)&nbsp;constitute (with or without notice or lapse of time or both) a default under,
(iii)&nbsp;require the Company to obtain any consent, approval or action of, make any filing with or give any notice to any Person as a result or under the terms of or (iv)&nbsp;result in the
creation or imposition of any Lien upon the Company or any of its properties or assets under, any contract, agreement, plan, permit or license to which the Company is a party. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.04</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governmental Approvals and Filings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No consent, approval or action of, filing with or notice to any
Governmental or Regulatory Authority on the part of the Company is required in connection with the execution and delivery of this Stockholders Agreement, other than the filing with the Commission
referred to in the next Section. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=14,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=354591,FOLIO='11',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_12"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="km1016_article_ix_general_provisions"> </A>
<A NAME="toc_km1016_5"> </A>
<BR></FONT><FONT SIZE=2><B>ARTICLE&nbsp;IX    <BR>    <BR>    GENERAL PROVISIONS    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.01</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Publicity.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company and BVF will provide each other with reasonable cooperation in connection with the
filings with the Commission required of the Company and the Stockholders in connection with the execution and delivery of this Stockholders Agreement, and will give the other an opportunity to review
such party's filing before it is submitted to the Commission. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.02</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Amendment and Waiver.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Stockholders Agreement may be amended, supplemented or modified only
by a written instrument duly executed by or on behalf of each party hereto. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;Any
term or condition of this Stockholders Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no such waiver shall be
effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such term or condition. No waiver by any party of any term or condition of this Stockholders
Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Stockholders Agreement on any future occasion. All remedies,
either under this Stockholders Agreement or by law or otherwise afforded, will be cumulative and not alternative. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.03</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notices.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;For all purposes of this Stockholders Agreement, the Company shall not be required to
recognize any notice purportedly delivered by or on behalf of any Stockholder or any other member of the Restricted Group unless such notice is delivered to the Company by or on behalf of BVF. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;All
notices, requests and other communications hereunder must be in writing and will be deemed to have been duly given only if delivered personally or by facsimile
transmission or mailed (first class postage prepaid) to the parties at the following addresses or facsimile numbers: </FONT></P>

<UL>

<P><FONT SIZE=2>If
to any Stockholder or other member of the Restricted Group, to: </FONT></P>

<P><FONT SIZE=2>BVF&nbsp;Inc.<BR>
One Sansome Street, 39th Floor<BR>
San Francisco, California 94104<BR>
Facsimile No.: (415)&nbsp;288-2394<BR>
Attn: Mark N. Lampert </FONT></P>

<P><FONT SIZE=2>with
a copy to: </FONT></P>

<P><FONT SIZE=2>Latham&nbsp;&amp;
Watkins<BR>
233 South Wacker Drive<BR>
Sears Tower, Suite&nbsp;5800<BR>
Chicago, Illinois 60606<BR>
Facsimile No.: (312)&nbsp;993-9767<BR>
Attn: Mark D. Gerstein,&nbsp;Esq. </FONT></P>


<P><FONT SIZE=2>If
to the Company, to: </FONT></P>

<P><FONT SIZE=2>Arena
Pharmaceuticals,&nbsp;Inc.<BR>
6166 Nancy Ridge Drive<BR>
San Diego, California 92121<BR>
Facsimile No.: (858)&nbsp;677-0065<BR>
Attn: Steven W. Spector,&nbsp;Esq. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=15,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=2351,FOLIO='12',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_13"> </A>
<UL>

<P><FONT SIZE=2>with
a copy to: </FONT></P>

<P><FONT SIZE=2>Milbank,
Tweed, Hadley&nbsp;&amp; McCloy&nbsp;LLP<BR>
1 Chase Manhattan Plaza<BR>
New York, NY 10005<BR>
Facsimile No.: (212)&nbsp;530-5219<BR>
Attn:&nbsp;&nbsp;Lawrence Lederman,&nbsp;Esq.<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Robert S. Reder,&nbsp;Esq. </FONT></P>

</UL>

<P><FONT SIZE=2>All
such notices, requests and other communications will (i)&nbsp;if delivered personally to the address as provided in this Section, be deemed given upon delivery, (ii)&nbsp;if delivered by
facsimile transmission to the facsimile number as provided in this Section, be deemed given upon receipt, and (iii)&nbsp;if delivered by mail in the manner described above to the address as provided
in this Section, be deemed given upon receipt (in each case regardless of whether such notice, request or other communication is received by any other person to whom a copy of such notice, request or
other communication is to be delivered pursuant to this Section). Any party from time to time may change its address, facsimile number or other information for the purpose of notices to that party by
giving notice specifying such change to the other parties hereto. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.04</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Stockholders Agreement and the Exhibits hereto supersede all prior discussions and
agreements among the parties hereto with respect to the subject matter hereof, and contains the sole and entire agreement among the parties hereto with respect to the subject matter hereof. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.05</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Third Party Beneficiary.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The terms and provisions of this Stockholders Agreement are intended solely for
the benefit of each party hereto and the other members of the Restricted Group, and it is not the intention of the parties to confer third-party beneficiary rights upon any other Person. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.06</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Assignment; Binding Effect.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Neither this Stockholders Agreement nor any right, interest or obligation
hereunder may be assigned by any parties hereto without the prior written consent of the other party hereto and any attempt to do so will be void. Subject to the preceding sentence, this Stockholders
Agreement is binding upon, inures to the benefit of and is enforceable by the parties hereto and their respective successors and assigns and legal representatives. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.07</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Specific Performance; Legal Fees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The parties acknowledge that money damages are not an adequate remedy for
violations of any provision of this Stockholders Agreement and that any party may, in such party's sole discretion, apply to a court of competent jurisdiction for specific performance for injunctive
or such other relief as such court may deem just and proper in order to enforce any such provision or prevent any violation hereof and, to the extent permitted by applicable law, each party waives any
objection to the imposition of such relief. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.08</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Headings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The headings used in this Stockholders Agreement have been inserted for convenience of reference
only and do not define or limit the provisions hereof. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.09</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Invalid Provisions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If any provision of this Stockholders Agreement is held to be illegal, invalid or
unenforceable under any present or future law, and if the intended rights of any party hereto under this Stockholders Agreement will not be forfeited in any material respect as a result thereof,
(i)&nbsp;such provision will be fully severable, (ii)&nbsp;this Stockholders Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a
part hereof and (iii)&nbsp;the remaining provisions of this Stockholders Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or
by its severance herefrom. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.10</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governing Law.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Stockholders Agreement shall be governed by and construed in accordance with the laws
of the State of Delaware applicable to a contract executed and performed in such State, without giving effect to the conflicts of laws principles thereof. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=16,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=756516,FOLIO='13',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_14"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.11</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Consent to Jurisdiction and Service of Process.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each party hereby irrevocably submits to the exclusive
jurisdiction of the United States District Court for the District of Delaware or any court of the State of Delaware in any action, suit or proceeding arising in connection with this Stockholders
Agreement, agrees that any such action, suit or proceeding shall be brought only in such court (and waives any objection based on </FONT><FONT SIZE=2><I>forum non conveniens  </I></FONT><FONT SIZE=2>or any other objection to venue therein to the
extent permitted by law), and agrees to delivery of service of process by any of the methods by which notices may be given
pursuant to </FONT><FONT SIZE=2><I>Section&nbsp;9.03</I></FONT><FONT SIZE=2>, with such service being deemed given as provided in such Section; </FONT><FONT SIZE=2><I>provided,
however</I></FONT><FONT SIZE=2>, that such consent to jurisdiction is solely for the purpose referred to in this </FONT><FONT SIZE=2><I>Section&nbsp;9.11 </I></FONT><FONT SIZE=2>and shall not be
deemed to be a general submission to the jurisdiction of said courts or in the State of Delaware other than for such purpose. Nothing herein shall affect the right of any party to serve process in any
other manner permitted by law or to commence legal proceedings or otherwise proceed against the other in any other jurisdiction. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.12</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Counterparts.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Stockholders Agreement may be executed in any number of counterparts, each of which will
be deemed an original, but all of which together will constitute one and the same instrument. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=17,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=936052,FOLIO='14',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_15"> </A>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, each party hereto has signed this Stockholders Agreement, or caused this Stockholders Agreement to be signed on its behalf, as of the date first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="90%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2>ARENA PHARMACEUTICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JACK LIEF</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2>Jack Lief</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BIOTECHNOLOGY VALUE FUND,&nbsp;L.P.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P., its general partner</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MARK N. LAMPERT</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BIOTECHNOLOGY VALUE FUND&nbsp;II,&nbsp;L.P.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P., its general partner</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MARK N. LAMPERT</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF INVESTMENTS,&nbsp;L.L.C.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P., its manager</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MARK N. LAMPERT</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
</TABLE>
<!-- insert table folio -->
<P ALIGN="CENTER"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=18,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=230496,FOLIO='15',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_16"> </A>
<!-- end of table folio -->
<TABLE WIDTH="90%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF PARTNERS&nbsp;L.P.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MARK N. LAMPERT</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MARK N. LAMPERT</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
INVESTMENT&nbsp;10,&nbsp;L.L.C.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P., as attorney-in-fact</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MARK N. LAMPERT</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="34%"><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=9,SEQ=19,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=17802,FOLIO='16',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<A NAME="page_km1016_1_17"> </A>
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="km1016_schedule_i"> </A>
<A NAME="toc_km1016_6"> </A>
<BR></FONT><FONT SIZE=2><B>SCHEDULE&nbsp;I    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="km1016_shares_of_common_stock_benefic__sha02488"> </A>
<A NAME="toc_km1016_7"> </A>
<BR></FONT><FONT SIZE=2><B>Shares of Common Stock Beneficially Owned by the Stockholders    <BR>  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="80%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="85%" ALIGN="LEFT"><FONT SIZE=1><B>Stockholder<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>Number</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="85%"><FONT SIZE=2>Biotechnology Value Fund,&nbsp;L.P.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2>2,263,745</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="85%"><FONT SIZE=2><BR>
Biotechnology Value Fund&nbsp;II,&nbsp;L.P.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1,453,102</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="85%"><FONT SIZE=2><BR>
BVF Investments,&nbsp;L.L.C.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2><BR>
3,714,365</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="85%"><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2><BR>
7,658,412</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="85%"><FONT SIZE=2><BR>
BVF&nbsp;Inc.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2><BR>
7,658,412</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="85%"><FONT SIZE=2><BR>
Investment&nbsp;10,&nbsp;L.L.C.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=2><BR>
227,200</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=10,SEQ=20,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=60134,FOLIO='17',FILE='DISK022:[03SAN6.03SAN1016]KM1016A.;6',USER='TCHAN',CD='18-JAN-2003;05:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kq1016_exhibit_a"> </A>
<A NAME="toc_kq1016_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT&nbsp;A    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kq1016_form_of_confidentiality_agreement"> </A>
<A NAME="toc_kq1016_2"> </A>
<BR></FONT><FONT SIZE=2><B>FORM OF CONFIDENTIALITY AGREEMENT    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>[ARENA
PHARMACEUTICALS LETTERHEAD] </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
2003&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>[BVF] </FONT></P>

<P><FONT SIZE=2>[ADDRESS] </FONT></P>

<P><FONT SIZE=2>Attn:
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] </FONT></P>

<P><FONT SIZE=2>Ladies
and Gentlemen: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Confidentiality Agreement is being entered into pursuant to Section&nbsp;5.01 of the Stockholders Agreement dated as of January&nbsp;17, 2003 between Arena
Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the "</FONT><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2>"), BVF&nbsp;Inc., a Delaware corporation
("</FONT><FONT SIZE=2><I>BVF</I></FONT><FONT SIZE=2>"), and the other signatories thereto (the "</FONT><FONT SIZE=2><I>Stockholders Agreement</I></FONT><FONT SIZE=2>"). Capitalized terms used herein
and not defined shall have the meaning given to such terms in the Stockholders Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a condition to the furnishing of information relating to the Company and its subsidiaries to any member of the Restricted Group and their respective Representatives, BVF and the other
signatories to this Confidentiality Agreement hereby agree with the Company that all information relating to the Company and its subsidiaries furnished by or on behalf of the Company to any member of
the Restricted Group or any of their respective Representatives, whether prior to or after your acceptance of this agreement and irrespective of the form of communication (e.g., whether written, oral
or in electronic medium), or learned by you in connection with the BVF Designee's or the BVF Observer's attendance at meetings of the Board of Directors, any committee thereof or through visits to the
Company or with its directors, officers or employees (such information, together with notes, memoranda, summaries, analyses, compilations and other writings relating thereto or based thereon prepared
by you or your Representatives being referred to herein as the "</FONT><FONT SIZE=2><I>Evaluation Material</I></FONT><FONT SIZE=2>"), will be kept strictly confidential from any person or entity
including, without limitation, any entity in which any member of the Restricted Group has any equity or other interest; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that the
Evaluation Material may be disclosed to any of your Representatives who needs to know such information for the purpose of assisting you in evaluating your investment in, and making decisions with
respect to, the Company (it being understood that such Representatives will be informed by you of the contents of this agreement and that, by receiving such information, such Representatives are
agreeing to be bound by this agreement). The term "</FONT><FONT SIZE=2><I>Evaluation Material</I></FONT><FONT SIZE=2>" does not include information which (i)&nbsp;is or becomes generally available
to the public other than as a result of disclosure by any member of the Restricted Group or their respective Representatives, or (ii)&nbsp;becomes available to any member of the Restricted Group or
any of their respective Representatives on a non-confidential basis from a source other than the Company or its affiliates or Representatives, </FONT><FONT SIZE=2><I>provided  </I></FONT><FONT SIZE=2>that neither any member of the Restricted Group
nor any of their respective Representatives is aware that such source is under an obligation (whether contractual, legal or
fiduciary) to the Company to keep such information confidential, or (iii)&nbsp;is or has been independently developed by any member of the Restricted Group or any of their respective Representatives
without reference to or use of any Evaluation Material. Any Evaluation Material shall be either returned or destroyed promptly following such date as provided by the Company's applicable document
retention policy in the case of Evaluation Material provided by the Company. For purposes hereof, the "</FONT><FONT SIZE=2><I>Representatives</I></FONT><FONT SIZE=2>" of any entity means such
entity's directors, officers, employees or legal, financial or accounting advisors and, in the case of the Restricted Group, includes the BVF Designee and the BVF Observer. The members of the
Restricted Group will be responsible for any breach of this agreement by any of their respective Representatives and agree to take all reasonable measures to restrain their respective Representatives
from prohibited or unauthorized disclosure or use of Evaluation Material or discussions with third parties as provided below. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=21,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=395366,FOLIO='blank',FILE='DISK022:[03SAN6.03SAN1016]KQ1016A.;1',USER='ALOEW',CD='18-JAN-2003;04:03' -->
<A NAME="page_kq1016_1_2"> </A>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any member of the Restricted Group or any of their respective Representatives is requested in any judicial or administrative proceeding or by any governmental or regulatory authority
to disclose any Evaluation Material, BVF will (i)&nbsp;give the Company prompt notice of such request so that the Company may seek an appropriate protective order and (ii)&nbsp;consult with the
Company as to the advisability of taking legally available steps to resist or narrow such a request. The members of the Restricted Group
will cooperate fully with the Company in obtaining such an order. If in the absence of a protective order any member of the Restricted Group or any of their respective Representatives is nonetheless
compelled to disclose Evaluation Material, the Company agrees that such disclosure may be made without liability hereunder. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
members of the Restricted Group hereby acknowledge that neither the Company nor any of its affiliates or Representatives makes any representation or warranty, express or implied, as
to the accuracy or completeness of any of the Evaluation Material. The members of the Restricted Group agree that neither the Company nor any of its affiliates or Representatives will have any
liability to any member of the Restricted Group or their respective Representatives resulting from use of any of the Evaluation Material. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is hereby acknowledged and agreed that money damages would not be a sufficient remedy for any breach of any provision of this agreement, and that in addition to all other remedies
which the Company may have, the Company will be entitled to specific performance and injunctive or other equitable relief as a remedy for any such breach. No failure or delay by the Company in
exercising any right, power or privilege hereunder will operate as a waiver thereof, nor will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of
any other right, power or privilege hereunder. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
agreement (i)&nbsp;contains the sole and entire agreement between the parties with respect to the subject matter hereof, (ii)&nbsp;may be amended, modified or waived only by a
separate written instrument duly executed by or on behalf of the Company and BVF, and (iii)&nbsp;shall be governed by and construed in accordance with the laws of the State of Delaware applicable to
a contract executed and performed in such State, without giving effect to the conflicts of laws principles thereof. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the foregoing correctly sets forth our agreement with respect to the matters set forth herein, please so indicate by signing this agreement in the space provided and returning such
signed copy to the Company, whereupon this agreement will constitute our binding agreement with respect to the matters set forth herein. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="90%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Very truly yours,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
ARENA PHARMACEUTICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 VALIGN="TOP"><FONT SIZE=2>Accepted and agreed to as of<BR>
the date first written above:</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=8><FONT SIZE=2><BR>
BIOTECHNOLOGY VALUE FUND,&nbsp;L.P.</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P., its general partner</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><I>President</I></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- insert table folio -->
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=22,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=53198,FOLIO='2',FILE='DISK022:[03SAN6.03SAN1016]KQ1016A.;1',USER='ALOEW',CD='18-JAN-2003;04:03' -->
<A NAME="page_kq1016_1_3"> </A>
<!-- end of table folio -->
<TABLE WIDTH="90%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=8><FONT SIZE=2><BR>
BIOTECHNOLOGY VALUE FUND&nbsp;II,&nbsp;L.P.</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P., its general partner</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><I>President</I></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=8><FONT SIZE=2><BR>
BVF INVESTMENTS,&nbsp;L.L.C.</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P., its manager</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><I>President</I></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=8><FONT SIZE=2><BR>
BVF PARTNERS&nbsp;L.P.</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><I>President</I></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=8><FONT SIZE=2><BR>
BVF&nbsp;INC.</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><I>President</I></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=8><FONT SIZE=2><BR>
INVESTMENT&nbsp;10,&nbsp;L.L.C.</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF Partners&nbsp;L.P., as attorney-in-fact</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=4><FONT SIZE=2><BR>
BVF&nbsp;Inc., its general partner</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>Mark N. Lampert</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2><I>President</I></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="33%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=23,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=1042785,FOLIO='3',FILE='DISK022:[03SAN6.03SAN1016]KQ1016A.;1',USER='ALOEW',CD='18-JAN-2003;04:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="ks1016_exhibit_b"> </A>
<A NAME="toc_ks1016_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT&nbsp;B    <BR>  </B></FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Sections&nbsp;1
and 2 of Article&nbsp;I of the Bylaws shall be amended and restated in their entirety to read as follows: </FONT></DD></DL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"SECTION&nbsp;1.</FONT><FONT
SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Annual Meeting.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;&nbsp;Except
as provided for in paragraph&nbsp;(B) below, the annual meeting of the stockholders of the Corporation shall be held on such date, at such time and at such
place within or without the State of Delaware as may be designated by the Board of Directors, for the purpose of electing Directors and for the transaction of such other business as may be properly
brought before the meeting. The Board of Directors may determine that an annual meeting shall not be held at any place, but shall instead be held solely by means of remote communication. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;&nbsp;As
contemplated by the Stockholders Agreement dated as of January&nbsp;17, 2003 (the "Stockholders Agreement"; capitalized terms used in this paragraph&nbsp;(B), in
paragraph&nbsp;(B) of Section&nbsp;2 of this Article&nbsp;I and in paragraph&nbsp;(C)(5) of Section&nbsp;10 of this Article&nbsp;I without definition shall have their meanings set forth in
the Stockholders Agreement, a copy of which is on file at the principal executive offices of the Corporation) by and among the Corporation and BVF&nbsp;Inc., a Delaware corporation, and the other
entities listed on the signature pages thereto (collectively, "BVF"), in the event that the Corporation does not (i)&nbsp;on or prior to May&nbsp;15<SUP>th</SUP> of any calendar year during the
Standstill Period and the first calendar year following the Standstill Termination Date (or, if the Standstill Termination Date occurs before the date of the annual meeting of stockholders for such
year, then in the calendar year in which the Standstill Termination Date occurs), give notice to the stockholders of the calling of the annual meeting of stockholders of the Corporation (including all
business noticed therefor) to be held on or before June&nbsp;30<SUP>th</SUP> of such calendar year, or (ii)&nbsp;conduct the annual meeting of the stockholders of the Corporation on or prior to
June&nbsp;30<SUP>th</SUP> of any such calendar year, BVF shall (x)&nbsp;in the case of any failure arising under clause&nbsp;(i), have the right to require the Corporation to call such annual
meeting by delivering notice thereof to the Corporation and, within five (5)&nbsp;business days following receipt by the Corporation of such notice from BVF, the Corporation shall cause the
Secretary of the Corporation to call and give notice of such annual meeting for a date not less than forty-five (45)&nbsp;nor more than sixty (60)&nbsp;days following the giving of
such notice to the stockholders of the Corporation in the manner contemplated by Section&nbsp;3 of this Article&nbsp;I, and such annual meeting will be held in accordance with such notice, and
(y)&nbsp;in the case of any failure arising under clause&nbsp;(ii), if such meeting can no longer be held, have the immediate right to require the calling of a special meeting of the stockholders
of the
Corporation, and the Corporation shall respond thereto as provided in the second sentence of paragraph&nbsp;(B) of Section&nbsp;2 of this Article&nbsp;I. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"SECTION&nbsp;2.</FONT><FONT
SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Special Meetings.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;&nbsp;Except
as otherwise provided in the Certificate of Incorporation or paragraph&nbsp;(B) below, a special meeting of the stockholders of the Corporation may be called at
any time by the Board of Directors or the President. Any special meeting of the stockholders shall be held on such date, at such time and at such place within or without the State of Delaware as the
Board of Directors or the officer calling the meeting may designate. The Board of Directors may determine that any special meeting of stockholders shall not be held at any place, but shall instead be
held solely by means of remote communication. At a special meeting of the stockholders, no business shall be transacted and no corporate action shall be taken other than that stated in the notice of
the meeting unless all of the stockholders are present in person or by proxy, in which case any and all business may be transacted at the meeting even though the meeting is held without notice. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;&nbsp;As
contemplated by the Stockholders Agreement, (i)&nbsp;unless the Corporation shall have delivered an Initial Offer Notice as contemplated by Section&nbsp;6.01 of
the Stockholders Agreement on or before October&nbsp;15, 2003, or (ii)&nbsp;if such notice was accepted by BVF and the Corporation fails to close such transaction as required by
Section&nbsp;6.01(c) of the Stockholders Agreement, BVF shall thereafter have the right to require the Corporation to hold a special meeting of the </FONT></P>

</UL>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=24,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=801937,FOLIO='blank',FILE='DISK022:[03SAN6.03SAN1016]KS1016A.;2',USER='TCHAN',CD='18-JAN-2003;05:51' -->
<A NAME="page_ks1016_1_2"> </A>
<UL>
<BR>

<P><FONT SIZE=2>
stockholders of the Corporation by delivering, at any time on or after November&nbsp;1, 2003 and prior to February&nbsp;1, 2004, notice thereof to the Corporation. Within five (5)&nbsp;business
days following receipt by the Corporation of such notice from BVF, the Corporation shall cause the Secretary of the Corporation to call and give notice of a special meeting to the stockholders of the
Corporation for a date not less than 45 nor more than 60&nbsp;days following the giving of notice by the Secretary of the Corporation to the stockholders of the Corporation in the manner
contemplated by the Section&nbsp;3 of this Article&nbsp;I, and such special meeting will be held in accordance with such notice." </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Paragraph&nbsp;(C)
of Section&nbsp;10 of Article&nbsp;I of the Bylaws shall be amended by adding the following: </FONT></DD></DL>
<UL>

<P><FONT SIZE=2>"(5)
As contemplated by the Stockholders Agreement, notwithstanding any other provision of these bylaws, nominations by stockholders of directors for election at any annual or special meeting of the
stockholders of the Corporation during the Standstill Period or at the first annual meeting of the stockholders of the Corporation following the Standstill Period shall in no event be required on a
date
earlier than forty-five (45)&nbsp;days after the giving of notice of the date of any such annual or special meeting of stockholders of the Corporation. </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>Article&nbsp;VII
of the Bylaws shall be amended and restated in its entirety to read as follows: </FONT></DD></DL>
<UL>

<P><FONT SIZE=2>"These
By-Laws and any amendment thereof may be altered, amended or repealed, or new By-Laws may be adopted, by the Board of Directors at any regular or special meeting by the
affirmative vote of a majority of all of the members of the Board, provided in the case of any special meeting at which all of the members of the Board are not present, that the notice of such meeting
shall have stated that the amendment of these By-Laws was one of the purposes of the meeting; but these By-Laws and any amendment thereof may be altered, amended or repealed or
new By-Laws may be adopted by the holders of a majority of the total outstanding stock of the Corporation entitled to vote at any annual meeting or at any special meeting, provided, in the
case of any special meeting, that notice of such proposed alteration, amendment, repeal or adoption is included in the notice of the meeting. Notwithstanding the foregoing, for so long as BVF has the
right to call an annual or special meeting of the stockholders of the Corporation under Section&nbsp;1 or Section&nbsp;2 of Article&nbsp;I of these By-Laws, neither
Section&nbsp;1(B) nor Section&nbsp;2(B) nor Section&nbsp;10(C)(5) of Article&nbsp;I of these By-Laws, nor this sentence, may be amended or supplemented, nor may any provision be
adopted that is inconsistent therewith, without the unanimous consent of all the members of the Board and the prior written consent of BVF." </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=25,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3",CHK=97637,FOLIO='2',FILE='DISK022:[03SAN6.03SAN1016]KS1016A.;2',USER='TCHAN',CD='18-JAN-2003;05:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03SAN1016_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_ki1016_1">Exhibit 10</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_ki1016_2">TABLE OF CONTENTS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ki1016_3">SCHEDULES</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ki1016_4">EXHIBITS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_kk1016_1">ARTICLE I DEFINITIONS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kk1016_2">ARTICLE II BOARD OF DIRECTORS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kk1016_3">ARTICLE III TRANSFER AND VOTING OF SHARES</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kk1016_4">ARTICLE IV STANDSTILL</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_km1016_1">ARTICLE V OTHER AGREEMENTS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_km1016_2">ARTICLE VI OFFER RIGHTS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_km1016_3">ARTICLE VII REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_km1016_4">ARTICLE VIII REPRESENTATIONS AND WARRANTIES OF THE COMPANY</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_km1016_5">ARTICLE IX GENERAL PROVISIONS</A></FONT><BR>
<UL>
<FONT SIZE=2><A HREF="#toc_km1016_6">SCHEDULE I</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_km1016_7">Shares of Common Stock Beneficially Owned by the Stockholders</A></FONT><BR>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kq1016_1">EXHIBIT A</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_kq1016_2">FORM OF CONFIDENTIALITY AGREEMENT</A></FONT><BR>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_ks1016_1">EXHIBIT B</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=CPULLIA,SEQ=,EFW="2101140",CP="ARENA PHARMACEUTICALS, INC.",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
